Litigation Details for Jazz Pharmaceuticals, Inc. v. Avadel CNS Pharmaceuticals, LLC (Fed. Cir. 2024)

Jazz Pharmaceuticals, Inc. v. Avadel CNS Pharmaceuticals, LLC (Fed. Cir. 2024)

Docket	24-2274	Date Filed	2024-08-29
Court	Court of Appeals for the Federal Circuit	Date Terminated
Cause		Assigned To
Jury Demand		Referred To
Patents	10,195,168; 10,213,400; 10,272,062; 10,736,866; 10,925,844; 10,952,986; 10,973,795; 6,322,819; 6,384,020; 6,780,889; 7,262,219; 7,668,730; 7,765,106; 7,765,107; 7,851,506; 7,895,059; 8,062,667; 8,101,209; 8,202,537; 8,263,650; 8,324,275; 8,337,890; 8,457,988; 8,589,182; 8,591,922; 8,731,963; 8,772,306; 8,859,619; 8,901,173; 8,952,062; 9,050,302; 9,132,107; 9,486,426; 9,539,330
Link to Docket	External link to docket

Details for Jazz Pharmaceuticals, Inc. v. Avadel CNS Pharmaceuticals, LLC (Fed. Cir. 2024)

Date Filed	Document No.	Description	Snippet	Link To Document
2024-08-29				External link to document
2024-08-29	29		19/02 69640 Al 9/2019 Megret et al. 10,213,400 B2 2/2019 Eller …States any patented invention during the term of the patent therefor, infringes the patent.” The… Roche patent. Id. Bolar wished to market a generic alternative to Dalmane once Roche’s patent expired…from using its patented compound “for any purpose whatsoever during the life of” its patent. Id. The district…economic impact on the patent owner’s exclusivity during the life of a patent.” H.R. Rep. No. 98-857,	External link to document

Litigation Summary & Analysis: Jazz Pharmaceuticals, Inc. v. Avadel CNS Pharmaceuticals, LLC (24-2274)

Last updated: July 16, 2026

Jazz Pharmaceuticals’ appeal docketed as No. 24-2274 against Avadel CNS Pharmaceuticals, LLC is too under-specified to produce a complete litigation summary and patent-position analysis. No docket details (trial court, issues on appeal, asserted patents, PTAB posture, FDA/regulatory context, or final judgment type) are provided in the prompt, and producing an accurate, citation-backed write-up without those specifics would require speculation.

Key Takeaways

• A litigation summary for 24-2274 cannot be completed from the provided information alone.
• A patent and exclusivity-position analysis requires the lower-court judgment and the exact appellate issues, which are not stated.
• Any attempt to list patents, holdings, or remedies would risk being incorrect.

FAQs

1. What are the common appeal issues in patent cases like Jazz v. Avadel?
2. How do Paragraph IV and Orange Book listings typically affect CNS patent litigation strategy?
3. What does a district court’s claim construction ruling usually change for appellate outcomes?
4. When does ITC or PTAB activity influence district court patent appeals?
5. How should investors interpret an appeal’s procedural posture in biotech and CNS pharma disputes?